A New Defense for the Heart
An innovative drug has shown encouraging results in patients suffering significant heart damage following a heart attack.
An international research team led by Hannover Medical School has published findings from the phase II clinical trial of the RNA-based drug CDR132L. Conducted across 80 centers in seven European countries and the UK, the study involved 294 patients treated post-heart attack to safeguard their heart muscle. The medication demonstrated particularly strong benefits in individuals with severely impaired cardiac function.
Study Design and Key Findings
Participants received either CDR132L or a placebo between 3 and 14 days after experiencing a heart attack. The drug was administered intravenously three times at four-week intervals. CDR132L works by inhibiting microRNA-132, a molecule responsible for harmful remodeling of the left ventricle following heart injury. Importantly, the treatment showed no adverse effects on liver and kidney function, blood cell production, or heart safety.
Cardior Pharmaceuticals, founded by Thomas Thum in 2016, developed CDR132L. In 2024, Novo Nordisk acquired the company and is continuing further research. Novo Nordisk is also conducting two additional clinical trials involving patients with chronic heart failure. The results of the HF-REVERT study related to this drug were published in the journal Nature Medicine.
“The most encouraging aspect is the pronounced response observed in patients whose hearts had already undergone significant remodeling and weakening.”
Johann Bauersachs
Thomas Thum emphasized, “These findings strongly support advancing the clinical development of this drug, especially for treating chronic heart failure.”
The outcomes of this trial open promising avenues for improving care in heart attack survivors and highlight the critical need for continued investigation in this field.
CDR132L represents a potential breakthrough in managing cardiovascular diseases, which remain a leading cause of death worldwide. The encouraging trial results suggest it could greatly enhance the quality of life for patients with severe cardiac events by offering new therapeutic options where treatment choices have been previously limited. Ongoing and future clinical studies will be essential to confirm the drug’s safety and effectiveness, marking an important milestone in the fight against heart disease.